307 related articles for article (PubMed ID: 3474582)
1. Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases.
Robert-Guroff M; Oleske JM; Connor EM; Epstein LG; Minnefor AB; Gallo RC
Pediatr Res; 1987 Jun; 21(6):547-50. PubMed ID: 3474582
[TBL] [Abstract][Full Text] [Related]
2. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia.
Robert-Guroff M; Giardina PJ; Robey WG; Jennings AM; Naugle CJ; Akbar AN; Grady RW; Hilgartner MW
J Immunol; 1987 Jun; 138(11):3731-6. PubMed ID: 3495568
[TBL] [Abstract][Full Text] [Related]
3. Antibody to human lymphotropic virus type III: immunologic status of homosexual contacts of patients with the acquired immunodeficiency syndrome and the acquired immunodeficiency-related complex.
Goldsmith JM; Kalish SB; Ostrow DG; Britz J; Chmiel JS; Wallemark CB; Phair JP
Sex Transm Dis; 1987; 14(1):44-7. PubMed ID: 2951878
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies and the course of HIV-induced disease.
Wendler I; Bienzle U; Hunsmann G
AIDS Res Hum Retroviruses; 1987; 3(2):157-63. PubMed ID: 3650100
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.
Ranki A; Weiss SH; Valle SL; Antonen J; Krohn KJ
Clin Exp Immunol; 1987 Aug; 69(2):231-9. PubMed ID: 3652531
[TBL] [Abstract][Full Text] [Related]
6. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).
Shearer GM; Bernstein DC; Tung KS; Via CS; Redfield R; Salahuddin SZ; Gallo RC
J Immunol; 1986 Oct; 137(8):2514-21. PubMed ID: 3489767
[TBL] [Abstract][Full Text] [Related]
7. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages.
Ljunggren K; Böttiger B; Biberfeld G; Karlson A; Fenyö EM; Jondal M
J Immunol; 1987 Oct; 139(7):2263-7. PubMed ID: 3498755
[TBL] [Abstract][Full Text] [Related]
8. Characterization of serum neutralization response to the human immunodeficiency virus (HIV).
Groopman JE; Benz PM; Ferriani R; Mayer K; Allan JD; Weymouth LA
AIDS Res Hum Retroviruses; 1987; 3(1):71-85. PubMed ID: 2441727
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of antibodies to HIV nuclear proteins in patients with the lymphadenopathy syndrome].
Schulte C; Meurer M; Fröschl M
Hautarzt; 1988 Jan; 39(1):45-8. PubMed ID: 3162727
[TBL] [Abstract][Full Text] [Related]
10. Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex.
Resnick L; diMarzo-Veronese F; Schüpbach J; Tourtellotte WW; Ho DD; Müller F; Shapshak P; Vogt M; Groopman JE; Markham PD
N Engl J Med; 1985 Dec; 313(24):1498-504. PubMed ID: 2999592
[TBL] [Abstract][Full Text] [Related]
11. HIV and HTLV-I antibody studies: pregnant women in the 1960s, patients with AIDS, homosexuals, and individuals with tropical spastic paraparesis.
Madden DL; Tzan NR; Roman GC; Detels R; Mundon FK; Fuccillo DA; Sever JL
Yale J Biol Med; 1987; 60(6):569-74. PubMed ID: 2893497
[TBL] [Abstract][Full Text] [Related]
12. Unique pattern of HTLV-III (AIDS-related) antigen recognition by sera from African children in Uganda (1972).
Saxinger C; Levine PH; Dean A; Lange-Wantzin G; Gallo R
Cancer Res; 1985 Sep; 45(9 Suppl):4624s-4626s. PubMed ID: 2990697
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of HTLV III/LAV and other viral antibodies in normal and at risk populations.
Ferrante P; Nardi G; Zanchetta N; Salvioni PM; Pagano A
Boll Ist Sieroter Milan; 1986; 65(5):357-60. PubMed ID: 3030363
[TBL] [Abstract][Full Text] [Related]
14. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
15. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline.
Lange JM; de Wolf F; Krone WJ; Danner SA; Coutinho RA; Goudsmit J
AIDS; 1987 Sep; 1(3):155-9. PubMed ID: 3126756
[TBL] [Abstract][Full Text] [Related]
16. HTLV-III: the etiologic agent of AIDS.
Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
[TBL] [Abstract][Full Text] [Related]
17. Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis.
Friedland GH; Saltzman BR; Rogers MF; Kahl PA; Lesser ML; Mayers MM; Klein RS
N Engl J Med; 1986 Feb; 314(6):344-9. PubMed ID: 3456076
[TBL] [Abstract][Full Text] [Related]
18. Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection.
Forster SM; Osborne LM; Cheingsong-Popov R; Kenny C; Burnell R; Jeffries DJ; Pinching AJ; Harris JR; Weber JN
AIDS; 1987 Dec; 1(4):235-40. PubMed ID: 3126771
[TBL] [Abstract][Full Text] [Related]
19. Differential reactivities of antibodies to HIV and HTLV-I in sera of suspected AIDS and ARC patients.
Aidoo M; Nishiwaki O; Akari H; Brandful JA; Ampofo W; Hayami M; Ayisi NK
West Afr J Med; 1994; 13(3):150-1. PubMed ID: 7841103
[TBL] [Abstract][Full Text] [Related]
20. [Clinical manifestations of acquired immunologic deficiency syndrome (AIDS)].
Goebel FD
Acta Med Austriaca; 1987; 14(1):1-4. PubMed ID: 3475926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
